Skip to main content

Leong Justin

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Leong Justin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 25, 2024 (view filing)Nov 223 daysLeong JustinChief Product OfficerSSaleReMed Common Stock−6.16K$243.09−$1.50M−22.1%21.7K after
Aug 6, 2024 (view filing)Aug 51 dayLeong JustinPresident, Asia Latin AmericaSSaleReMed Common Stock−48.0K$217.07−$10.4M−71.9%18.7K after
Nov 23, 2022 (view filing)Nov 221 dayLeong JustinPresident, Asia Latin AmericaSSaleReMed Common Stock−3.78K$229.50−$866.8K−5.9%59.8K after